Drug Profile


Alternative Names: AMG-103; Blincyto; MEDI-538; MT-103

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Micromet Inc
  • Developer Amgen; Astellas Pharma; M. D. Anderson Cancer Center; Micromet Inc; National Cancer Institute (USA)
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - B cell prolymphocytic leukaemia; Acute lymphoblastic leukaemia; B cell lymphoma; Mantle-cell lymphoma; T cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Hairy cell leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute lymphoblastic leukaemia
  • Phase II/III Non-Hodgkin's lymphoma
  • Phase II Diffuse large B cell lymphoma
  • Discontinued Chronic lymphocytic leukaemia

Most Recent Events

  • 14 Feb 2017 Amgen has patent protection for blinatumomab in USA and European Union (Amgen 10-k, February 2017)
  • 14 Feb 2017 Amgen files sBLA for Ph+ B-cell precursor Acute lymphoblastic leukaemia (Second-line therapy or greater) in USA
  • 11 Jan 2017 Phase-II clinical trials in Diffuse large B cell lymphoma (Newly diagnosed, Adjunctive treatment) in Spain (IV) (EudraCT2016-002190-35)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top